evipedia.ai
← Back

Lemongrass to Treat Cancer

Evidence Review created on 10/23/2026 using AI4L / Opus 5.5

Also known as: Lemon Grass, Cymbopogon citratus, Cymbopogon flexuosus, West Indian Lemongrass, East Indian Lemongrass, Fever Grass, Lemongrass Oil, Lemongrass Essential Oil

Motivation

Lemongrass (Cymbopogon citratus) is a tall tropical grass whose lemon-scented stalks flavor Southeast Asian cooking and whose leaves are brewed as an herbal tea; the oil distilled from it is used in perfumes, soaps and aromatherapy. Most of its scent comes from citral, a reactive plant compound that laboratory scientists have studied for its effects on how cancer cells grow and die.

Interest in lemongrass as a cancer remedy rose in the mid-2000s, when a laboratory report on citral spread through the press and online, and some people with cancer began drinking the tea every day. Since then, studies of lemongrass extracts and oil in cells and animals have accumulated, alongside open questions about how much citral actually reaches the body, how lemongrass might interact with cancer drugs, and whether one minor component of the oil carries its own cancer concern.

This review examines lemongrass as a treatment for cancer, used alone or alongside standard care: the type and strength of the evidence, possible harms and drug interactions, the forms and amounts people use, and how it fits a proactive, longevity-minded approach to living with cancer.

Benefits - Risks - Protocol - Conclusion

Selected expert commentary and academic articles that discuss lemongrass, citral and cancer in depth.

None of the six priority sources (Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension, Lifespan.io) has published content discussing lemongrass in relation to cancer: their sites mention it only in recipes, product ingredient lists or a passing seizure-research note.

Grokipedia

Cymbopogon citratus

Encyclopedic overview of the lemongrass plant, its citral-dominated essential oil, traditional uses and reported pharmacological activities; useful botanical background, not a cancer-specific evidence assessment.

Examine

No Examine article on lemongrass exists; the site lists only a research-feed summary of a lemongrass mouthwash trial in children with gum inflammation.

ConsumerLab

No ConsumerLab article on lemongrass exists; the term appears only inside unrelated product reviews and warnings about essential-oil sellers.

Systematic Reviews

Systematic reviews involving lemongrass cover its antifungal activity and general physiological effects; none addresses cancer.

Both the claimed effect (cancer treatment) and the principal risks (kidney effects, contact allergy, myrcene exposure, displacement of standard treatment) are unrepresented: no systematic review or meta-analysis covers either.

Mechanism of Action

Lemongrass leaves contain a small amount of essential oil dominated by citral, a mixture of two aldehydes (geranial and neral) that makes up 65–85% of the oil (Habib et al., 2021); the oil also carries β-myrcene (a fragrance hydrocarbon), and leaf tea adds polyphenols (plant antioxidant compounds) and polysaccharides (long sugar chains). The proposed anticancer actions come from cell and rodent studies:

  • Apoptosis (programmed cell death): citral activates caspase-3 (an enzyme that executes apoptosis) in blood-cancer cell lines (Dudai et al., 2005); lemongrass extract acts through ROS (reactive oxygen species, unstable oxygen molecules) (Philion et al., 2017).
  • Survival signaling: citral blocks Src/STAT3 (a growth-and-survival signaling pathway) in small-cell lung cancer cells (Maruoka et al., 2018).
  • Stem-like cancer cells: citral inhibits ALDH1A3 (an aldehyde dehydrogenase enzyme marking treatment-resistant cells) (Thomas et al., 2016) and disrupts microtubules (the scaffolding cells use to divide) (Bailly, 2020).
  • Drug pumps: lemongrass oil and citral lower P-glycoprotein (a pump that expels chemotherapy drugs) gene expression in resistant cells (Mukhtar et al., 2023).
  • Immune support: lemongrass polysaccharides raised immune markers in tumor-bearing mice (Bao et al., 2015).

Competing view: citral is unstable, poorly bioavailable and only weakly selective for cancer cells (Bailly, 2020). Pharmacology: in rats it is quickly oxidized to acids and glucuronides (conjugates the body excretes), with about half an oral dose in urine within 24 hours (Diliberto et al., 1990); the enzymes involved, human half-life, tissue distribution and tumor levels are uncharacterized.

Historical Context & Evolution

Lemongrass has long been used in South and Southeast Asian, African and Latin American folk medicine — hence “fever grass” — for fever, digestive complaints, anxiety and sleep. In Brazil its leaf tea is among the most popular herbal remedies; a 1986 volunteer program found it non-toxic over two weeks but without sleep-inducing or anxiety-reducing effects (Leite et al., 1986).

Cancer interest began in Thai and Japanese laboratories studying Thai cuisine: lemongrass extract blocked chemical mutagens (DNA-damaging agents) in bacterial assays (Vinitketkumnuen et al., 1994) and reduced carcinogen-induced precancerous lesions in rat colon (Suaeyun et al., 1997) and liver (Puatanachokchai et al., 2002). In 2005 an Israeli group reported that citral, at concentrations comparable to a cup of lemongrass tea, induced apoptosis in blood-cancer cell lines (Dudai et al., 2005). Press coverage led some patients to drink several cups daily and sellers to market citral supplements, although only cultured cells had been studied (Schwarcz, 2017).

Laboratory work then widened to oils, extracts and nano-formulated citral, including mouse tumor studies. Toxicology moved the other way for one constituent: β-myrcene caused kidney and liver tumors in rodents (National Toxicology Program, 2010), IARC (International Agency for Research on Cancer) evaluated it in its 2019 Monographs volume (IARC, 2019), and the FDA (US Food and Drug Administration) withdrew authorization of synthetic myrcene as a flavoring in 2018 (FDA, 2018). No human cancer trial has been registered; the question remains open rather than settled either way.

Expected Benefits

High 🟩 🟩 🟩

Reduced Gum Inflammation ⭕️ Not Central to Treat Cancer

A 0.25% lemongrass oil mouthwash used twice daily for 21 days reduced gingivitis (gum inflammation) on the gingival index, a validated clinical scale, in randomized trials from independent Indian groups led by Dany (Dany et al., 2015), Akula (Akula et al., 2021) and Wasey (Wasey et al., 2023), each comparing it with chlorhexidine (a standard antiseptic rinse) and with professional cleaning alone. This bears on oral health during cancer treatment, not on tumors. All three trials were small (60 participants each) and short.

Magnitude: At day 21, mean gingival index was 0.98 with lemongrass mouthwash, 1.11 with chlorhexidine and 1.41 with cleaning alone (60 children; p=0.001 across groups, p being the probability of a chance result; no 95% CI (confidence interval) reported); plaque scores did not differ significantly between groups (Akula et al., 2021).

Reduced Anxiety From Inhaled Oil ⭕️ Not Central to Treat Cancer

Inhaled lemongrass essential oil lowered self-rated state anxiety in randomized trials from independent groups led by Goes in Brazil, in 40 healthy men facing a stress test (Goes et al., 2015), and Maybodi in Iran, in 38 patients during deep dental cleaning (Maybodi et al., 2025). This bears on treatment-related anxiety, not on tumors. Lemongrass tea showed no anxiety effect in a double-blind study (Leite et al., 1986), so the effect is tied to the aroma. Both trials were small and single-session.

Magnitude: On the STAI-S (Spielberger state-anxiety questionnaire, a validated scale), anxiety fell 6.9 points with lemongrass aroma and rose 2.4 points without it (38 patients; p=0.006 between groups; no 95% CI reported) (Maybodi et al., 2025).

Medium 🟩 🟩

No benefit reaches Medium: the one randomized trial of a cancer-relevant infection (oral thrush) found no significant difference in its intention-to-treat analysis (analysis of all randomized patients) (Wright et al., 2009), and every anticancer finding comes from cell-culture or rodent studies.

Low 🟩

Treatment of Oral Thrush ⚠️ Conflicted ⭕️ Not Central to Treat Cancer

Oral thrush (oropharyngeal candidiasis, a mouth yeast infection) complicates cancer treatment but is not a tumor. A randomized trial in 90 HIV-positive (human immunodeficiency virus) patients compared lemongrass infusion with gentian violet (Wright et al., 2009); completers favored lemongrass; intention-to-treat analysis did not. Net: unconfirmed.

Magnitude: Clinical cure RR (relative risk, the ratio of cure rates) 1.67 (95% CI 0.87–3.20) for lemongrass infusion versus 0.5% gentian violet, an antifungal dye, not significant, in the Cochrane analysis of this trial (Pienaar et al., 2010); in the 83 patients who completed the trial, lemongrass outperformed gentian violet (p<0.05).

Speculative 🟨

Tumor Growth Inhibition

Lemongrass extract, oil and citral killed many cancer cell lines and slowed human colon and prostate tumors grown in mice (Ruvinov et al., 2019; Nguyen et al., 2019). Basis: cell and animal data only.

Prevention of Cancer After Carcinogen Exposure ⭕️ Not Central to Treat Cancer

In rats given chemical carcinogens, lemongrass extract reduced DNA damage and precancerous colon and liver lesions (Suaeyun et al., 1997; Puatanachokchai et al., 2002). This bears on prevention, not treatment; animal data only.

Enhanced Chemotherapy Effect

Lemongrass oil and citral increased doxorubicin killing of drug-resistant cancer cells (Mukhtar et al., 2023); extract added to FOLFOX further slowed mouse colon tumors (Ruvinov et al., 2019). Basis: cell and animal data only.

Mice given lemongrass extract together with FOLFOX lost less weight than mice given FOLFOX alone (Ruvinov et al., 2019). This bears on chemotherapy tolerance, not on tumors; the basis is a single animal study.

Benefit-Modifying Factors

  • Genetic polymorphisms: No study links any gene variant to lemongrass response. Citral is an aldehyde, so variants in aldehyde-clearing enzymes could in theory change exposure; this is untested.
  • Tumor biomarkers: In mice, citral slowed breast tumors engineered to overexpress ALDH1A3 (Thomas et al., 2016); tumor ALDH1A3 status is the only proposed response marker, untested in humans.
  • Cancer type: Activity appears across blood, colon, lung, prostate and breast cell lines, with blood-cancer cells responding at tea-like citral concentrations (Dudai et al., 2005); no human tumor type has been shown to respond.
  • Sex: No sex differences in anticancer effect have been studied; the mouse mammary-cancer prevention study used only females (Bidinotto et al., 2011), and the rat liver study only males (Puatanachokchai et al., 2002).
  • Pre-existing conditions: The oral thrush data come from people with HIV (Wright et al., 2009). Reduced kidney function or ongoing chemotherapy shift the balance toward risk (see Risks and Interactions).
  • Age: No age-specific data exist; older adults usually have less kidney reserve and take more medications, narrowing any margin between possible benefit and harm.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: human harm data for lemongrass come from single-group volunteer studies, patch-test series without comparison groups, case reports, and cohort studies of alternative medicine in general.

Medium 🟥 🟥

No risk reaches Medium: no controlled trial or comparison-group study has measured a harm of lemongrass itself; the only comparison-group data concern alternative medicine generally and are therefore indirect.

Low 🟥

Higher Risk of Death When Used Instead of Standard Treatment

Using alternative remedies instead of surgery, radiation, chemotherapy or hormone therapy for curable cancer was linked to higher mortality in a matched US cancer-registry cohort (Johnson et al., 2018). Lemongrass was not studied specifically, so this evidence is indirect.

Magnitude: HR (hazard ratio, relative rate of death over time) 2.50 (95% CI 1.88–3.27) for alternative medicine alone versus standard treatment, in 840 matched patients with non-metastatic breast, prostate, lung or colorectal cancer; five-year survival was 54.7% versus 78.3%.

Decline in Kidney Function ⚠️ Conflicted

In 105 healthy adults drinking tea from 2–8 g of leaf daily, eGFR (estimated glomerular filtration rate, a kidney-filtering measure) fell by day 30 (Ekpenyong et al., 2015). A two-week volunteer study found no kidney-marker change (Leite et al., 1986). Net: a plausible but uncontrolled, unreplicated kidney signal.

Magnitude: eGFR and creatinine clearance (a related filtering measure) fell significantly from baseline at day 30 in all three dose groups, and by day 10 in women at 8 g (no control group); the accessible literature reports no outcome figure for the size of the decline.

Allergic Contact Dermatitis

Lemongrass oil and citral are recognized skin sensitizers (substances causing a delayed allergic rash). Patch-test (skin allergy test) series from German-speaking and other European clinics document reactions (Geier et al., 2022; Heydorn et al., 2003); one sensitized patient’s rash recurred after lemongrass tea (Bleasel et al., 2002).

Magnitude: 2.6% of dermatitis patients patch-tested with lemongrass oil reacted (in a 10,930-patient series tested with 12 essential oils), and 28 of 586 hand-eczema patients reacted to 2% citral (no control group in either series).

Speculative 🟨

Rodent Carcinogenicity of β-Myrcene

β-Myrcene, a minor lemongrass-oil component, caused kidney and liver tumors in rodents at high doses (National Toxicology Program, 2010). Citral itself produced no attributable tumors (Ress et al., 2003). Basis: animal data only.

Altered Chemotherapy Effect

Lemongrass oil and citral changed liver drug-metabolizing enzymes in rats (Li et al., 2018), which could alter chemotherapy levels in either direction. Basis: mechanistic and animal data only.

Liver and Stomach Injury From Concentrated Oil

Lemongrass essential oil above about 1,500 mg/kg damaged rat stomach and liver (Fandohan et al., 2008); citral at 2,000 mg/kg injured mouse liver (Tang et al., 2018). Basis: animal data only.

Harm to the Fetus

Citral given to pregnant rats increased embryo loss and minor skeletal anomalies, with no safe dose identified down to 60 mg/kg (Nogueira et al., 1995). Basis: animal data only.

Risk-Modifying Factors

  • Genetic polymorphisms: No gene variant is known to change lemongrass toxicity. Allergic reactions to citral cluster in people already sensitized to other fragrances (Heydorn et al., 2003).
  • Baseline biomarkers: A low baseline eGFR or high serum creatinine leaves less margin for the kidney-function decline seen with daily tea (Ekpenyong et al., 2015).
  • Sex: Women at the 8 g dose showed eGFR decline by day 10, earlier than men (Ekpenyong et al., 2015); women are over-represented among patients sensitized to essential oils (Geier et al., 2022).
  • Pre-existing conditions: Chronic kidney disease, eczema or fragrance allergy, pregnancy, and active chemotherapy raise concern; people with curable cancer face the largest risk if lemongrass displaces standard treatment (Johnson et al., 2018).
  • Age: Essential-oil sensitization was more frequent in patients aged 40 or older (Geier et al., 2022); kidney reserve declines with age, leaving older adults less margin for renal effects.

Key Interactions & Contraindications

No human interaction or pharmacokinetic study (of how the body absorbs and clears it) of lemongrass exists, so every interaction below rests on animal, cell or mechanistic data and is theoretical.

Prescription drugs:

  • Chemotherapy (doxorubicin, paclitaxel, FOLFOX): Caution (theoretical). Cell and mouse studies show added effect (Mukhtar et al., 2023; Ruvinov et al., 2019), but altered drug metabolism could change toxicity or efficacy. Mitigation: disclosure to the oncology team; food-level amounts during treatment cycles.
  • CYP2B- and CYP1A2-metabolized drugs (cyclophosphamide, bupropion, theophylline, clozapine): Monitor (theoretical). β-Myrcene induced CYP2B, and citral induced CYP1A2 and CYP2E1 (liver drug-metabolizing enzymes) in rodents (De-Oliveira et al., 1997; Tang et al., 2018), possibly shifting drug levels. Mitigation: drug-level or response monitoring.
  • CYP3A4-metabolized drugs (docetaxel, irinotecan, tamoxifen): Monitor (theoretical). Lemongrass oil and citral reduced CYP3A activity in rats (Li et al., 2018) and CYP3A4 (a drug-metabolizing liver enzyme) expression in cancer cells (Mukhtar et al., 2023); consequence: higher drug levels. Mitigation: oncology-team review.
  • Glutathione S-transferase substrates (busulfan, chlorambucil, melphalan): Monitor (theoretical). Citral induces glutathione S-transferase (a detoxifying liver enzyme), per the monograph of a cancer center earning from conventional care (MSKCC); consequence: altered drug levels or side effects. Mitigation: oncology-team review.
  • Nephrotoxic (kidney-damaging) drugs (cisplatin, methotrexate, aminoglycoside antibiotics): Caution (theoretical). Daily tea lowered eGFR in volunteers (Ekpenyong et al., 2015); combined use could add kidney injury. Mitigation: creatinine and eGFR checks before each cycle.
  • Diuretics (drugs that increase urine output: furosemide, hydrochlorothiazide): Monitor (theoretical). Lemongrass tea increased urine volume and urinary electrolyte loss (Ekpenyong et al., 2015); consequence: dehydration or low potassium or sodium. Mitigation: electrolyte checks.
  • Metformin: Monitor (theoretical). Metformin diminished citral’s killing of sarcoma (connective-tissue cancer) cells in vitro by quenching ROS (Duan et al., 2021); consequence: any anticancer action of citral may be lost. No glucose interaction is reported.

Over-the-counter medications:

  • NSAIDs (non-steroidal anti-inflammatory drugs: ibuprofen, naproxen): Caution (theoretical). NSAIDs reduce kidney blood flow; added to the eGFR decline seen with daily tea (Ekpenyong et al., 2015), kidney injury risk could rise. Mitigation: lowest effective NSAID dose, kidney checks.
  • Acetaminophen: No interaction found in rats (theoretical for humans): lemongrass oil and citral did not change acetaminophen liver toxicity (Li et al., 2018). Severity: none identified.

Supplements:

  • Other citral-rich botanicals (lemon balm, Litsea cubeba oil, lemon myrtle): Caution, additive (theoretical). These oils are also citral-dominated (Nagata et al., 2024); stacking raises total citral dose and allergy risk. Mitigation: one citral source at a time.
  • High-dose antioxidants (vitamin C, vitamin E, N-acetylcysteine): Caution during chemotherapy or radiotherapy (theoretical). Additive antioxidant action could blunt treatments that kill cells through oxidative stress, as metformin blunted citral (Duan et al., 2021). Mitigation: oncology-team review.
  • Diuretic herbs (dandelion, juniper, parsley): Monitor, additive (theoretical). Combined with lemongrass’s diuretic effect (Ekpenyong et al., 2015), fluid and electrolyte loss could increase. Mitigation: hydration and electrolyte checks.
  • Myrcene-rich products (hops extracts, terpene blends): Caution, additive (theoretical). Adds β-myrcene, a rodent carcinogen (National Toxicology Program, 2010). Mitigation: avoiding concentrated combinations.

Other interventions:

  • Radiotherapy: Caution (theoretical). Applying lemongrass oil, a known skin sensitizer (Geier et al., 2022), to irradiated skin could add irritation or allergic dermatitis. Mitigation: no topical oil on the treatment field.

Populations who should avoid Lemongrass:

  • Pregnant women: citral caused embryo loss and skeletal anomalies in rats (Nogueira et al., 1995); Memorial Sloan Kettering’s monograph says avoidance “may be advisable” (MSKCC) — a cancer center whose revenue comes from conventional cancer care, though it does not sell lemongrass.
  • People with a positive patch test to lemongrass oil, citral or fragrance mix (Geier et al., 2022).
  • People with chronic kidney disease (no source gives a threshold) (Ekpenyong et al., 2015).
  • People with curable cancer who would use lemongrass in place of standard treatment (Johnson et al., 2018).

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Alongside, not instead of, standard treatment: Keeping surgery, radiation and drug therapy in place prevents the higher death risk linked to replacing them with alternative remedies (Johnson et al., 2018).
  • Food-level amounts: Culinary use or short courses of tea from 2 g dried leaf daily, the lowest dose tested, reduce kidney-function exposure; even 2 g lowered eGFR by day 30 (Ekpenyong et al., 2015).
  • No essential oil by mouth: Avoiding ingestion of concentrated oil prevents the stomach and liver injury seen in rats at high doses (Fandohan et al., 2008).
  • Kidney checks: Creatinine and eGFR at baseline and after 4 weeks of daily tea detect the decline reported by day 30; no source sets a stopping threshold, so any sustained fall from baseline is the usual trigger.
  • Patch test before topical use: Oil diluted to 1% or less, applied to a small skin area for 48 hours, screens for allergic contact dermatitis before wider use.
  • Oncology-team disclosure: Reporting lemongrass use lets the treating team check timing against chemotherapy and avoid theoretical enzyme or antioxidant interactions.
  • Low-myrcene products: Batch GC-MS certificates (gas chromatography–mass spectrometry, listing each compound) allow choosing oils low in β-myrcene, limiting exposure to a rodent carcinogen (National Toxicology Program, 2010).
  • Avoidance in pregnancy: Not using lemongrass beyond food amounts while pregnant avoids the fetal harm seen in rats (Nogueira et al., 1995).

Therapeutic Protocol

No standard anticancer protocol exists, and no oncology guideline uses lemongrass to treat cancer. Doses below come from human studies of other outcomes; other parameters without a citation (timing, cycling, titration) reflect common practice.

  • Mouthwash (gum health): A 0.25% lemongrass oil mouthwash twice daily for 21 days was the regimen in the gingivitis trials (Dany et al., 2015); it is rinsed, not swallowed.
  • Tea (most studied form): Infusion from 2, 4 or 8 g dried leaf powder once daily for 30 days in healthy volunteers (Ekpenyong et al., 2015); eGFR fell by day 30 at every dose.
  • Popularized approach: Several cups of tea daily, popularized after the 2005 Ben-Gurion University citral study; about 1 g of lemongrass per cup matches the citral concentration used on cells (Dudai et al., 2005; Schwarcz, 2017).
  • Extracts and oil (alternative approach): Ethanolic extracts and essential oil have been dosed only in animals (Ruvinov et al., 2019); no human anticancer dose exists, and oral essential oil is not part of any tested protocol.
  • Conventional oncology approach: Integrative oncology services list lemongrass as an herb with limited human data and no established anticancer use (MSKCC), a cancer center earning revenue from conventional care.
  • Time of day: No timing data exist; tea caused no sleepiness in a double-blind volunteer study (Leite et al., 1986), so any time is used; evening tea may increase night urination.
  • Half-life: Not measured in humans; in rats citral is metabolized quickly, with about half an oral dose excreted in urine within 24 hours (Diliberto et al., 1990).
  • Single or split dose: Human studies used one daily cup (Ekpenyong et al., 2015); splitting is untested, though rapid clearance in rats suggests split intake gives steadier exposure.
  • Genetic polymorphisms: No pharmacogenetic data exist; variants in aldehyde-metabolizing enzymes could in theory alter citral clearance.
  • Sex: Women at 8 g daily showed earlier eGFR decline than men (Ekpenyong et al., 2015), so lower doses carry less renal signal in women.
  • Age: Older adults, with less kidney reserve and more medications, have the narrowest margin; no age-specific dosing exists.
  • Baseline biomarkers: Baseline eGFR and creatinine set the safety margin; tumor ALDH1A3 status is a proposed, mouse-only response marker (Thomas et al., 2016).
  • Pre-existing conditions: Kidney disease, fragrance allergy and pregnancy weigh against use; active chemotherapy calls for oncology-team review because of theoretical interactions.

Discontinuation & Cycling

  • Duration: No long-term human data exist; the longest studied daily exposure is 30 days (Ekpenyong et al., 2015). As a cancer measure it has no defined duration; as food it is lifelong.
  • Withdrawal effects: None reported; lemongrass has no known dependence or rebound effect.
  • Tapering: Not needed; no tapering protocol exists, and stopping at once is common practice.
  • Cycling: Not studied for efficacy; breaks with kidney re-testing are common practice given the time-dependent eGFR decline seen with daily tea (Ekpenyong et al., 2015).
  • Stopping triggers: A new rash, a sustained fall in eGFR, pregnancy, or a new interacting cancer drug are the usual reasons to stop.

Sourcing and Quality

  • Form: Fresh stalks and dried-leaf tea deliver citral plus polyphenols at food-level doses; essential oil concentrates citral and β-myrcene and is not food unless labeled food-grade.
  • Species and composition: Both C. citratus and C. flexuosus are listed as generally recognized as safe (GRAS) lemongrass sources (21 CFR 182.20); oil composition varies, with 63% citral in one batch (Viktorová et al., 2020).
  • Contaminants: Lemongrass grows in lead-contaminated soil and is proposed for cleaning such soils (Sete da Cruz et al., 2024), so heavy-metal-tested or certified organic sources reduce exposure.
  • What to look for: GC-MS certificates for oils, food-grade labeling for anything taken internally, and third-party testing (USP (United States Pharmacopeia) or NSF International seals) where offered.
  • Brands: No commercial product has been tested in human cancer research, and ConsumerLab has not reviewed lemongrass products; mouse-study extracts were laboratory-made.
  • Citral supplements: Citral supplements marketed after 2005 lack human data (Schwarcz, 2017).

Practical Considerations

  • Time to effect: Unknown; no human study has measured an anticancer effect. Kidney-function changes appeared within 10–30 days of daily tea (Ekpenyong et al., 2015).
  • Common pitfalls: Substituting lemongrass for standard treatment; equating cell-culture concentrations with blood levels; swallowing essential oil; using it during chemotherapy without telling the oncology team; stacking several citral-rich products.
  • Regulatory status: In the US, lemongrass oil is GRAS as a food ingredient (21 CFR 182.20), not an approved cancer drug; the FDA withdrew authorization of synthetic myrcene as a flavoring in 2018 (FDA, 2018).
  • Cost and access: Inexpensive and widely sold as fresh stalks, dried tea and oil; cost is not a barrier.
  • Research funding gap: Lemongrass is cheap and unpatentable, so no manufacturer has a financial incentive to fund trials, and insurers and health systems neither pay for it nor fund its study; this structurally biases research toward patentable drugs.

Interaction with Foundational Habits

  • Sleep: None (direct): in a double-blind study of 50 volunteers, lemongrass tea did not change sleep onset or quality (Leite et al., 1986). Its diuretic effect (Ekpenyong et al., 2015) may cause night urination if taken in the evening.
  • Nutrition: Compatible (indirect): lemongrass fits plant-rich Thai and Vietnamese cooking. Its diuretic effect raised urinary electrolyte losses in volunteers (Ekpenyong et al., 2015), so fluid and electrolyte intake (potassium-rich vegetables) matter with daily tea. No nutrient depletion is documented.
  • Exercise: None established (indirect): no published human data. A placebo-controlled trial of 200 mg lemongrass extract on aerobic fitness, with an industry collaborator (NCT07195240), passed its estimated June 2026 completion with no results posted. Increased urine output before endurance sessions may affect hydration.
  • Stress management: Indirect: inhaled lemongrass oil reduced self-rated anxiety in 40 men facing a stress test (Goes et al., 2015), whereas tea did not reduce anxiety in a double-blind study (Leite et al., 1986); aroma, not tea, is the relevant form.

Monitoring Protocol & Defining Success

Baseline testing before starting regular lemongrass tea or extract covers kidney function (serum creatinine and eGFR), a full blood count and a liver enzyme, plus the oncology team’s own tumor assessments; anyone planning topical oil use adds a small-area patch test. These baselines matter because the human data are uncontrolled, so each person’s own starting values are the main reference.

Ongoing monitoring follows this cadence: kidney function at 4 weeks, then every 3 months while daily use continues; blood count and liver enzyme every 3 months; tumor assessments on the schedule set by the oncology team. Any sustained fall in eGFR, rise in creatinine or liver enzyme, or new rash is a reason to stop and review. Success for the goal can only be judged by standard tumor-response measures, since no lemongrass-specific marker of benefit exists.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Serum creatinine 0.7–1.3 mg/dL men; 0.6–1.1 mg/dL women (standard reference range) Safety check: a rise stops or reduces use Rose with daily tea in volunteers (Ekpenyong et al., 2015); no fasting needed; avoid heavy exercise and large meat meals 24 hours before; pair with eGFR
eGFR No established target; track change from own baseline Safety check: a sustained fall stops use Estimated glomerular filtration rate, calculated from creatinine; fell by day 30 with daily tea (Ekpenyong et al., 2015); cystatin C (a second filtration marker) is the best paired test
Hemoglobin 13.5–17.5 g/dL men; 12.0–15.5 g/dL women (standard reference range) Expected change: tea raised hemoglobin in volunteers Raised along with red cell count in the same volunteer trials (Ekpenyong et al., 2015); chemotherapy lowers it, so trends need both contexts; part of a full blood count
White blood cell count 4.5–11.0 × 10⁹/L (standard reference range) Safety check: tea lowered total white cells in volunteers Same volunteer trials (Ekpenyong et al., 2015); chemotherapy also lowers counts; morning draw for consistency
ALT 7–56 U/L (standard reference range; varies by laboratory) Safety check: a rise stops concentrated oil or extract ALT (alanine aminotransferase) is a liver enzyme; liver injury seen only at high oil doses in rodents (Fandohan et al., 2008); avoid strenuous exercise 24 hours before
Tumor burden (imaging, tumor markers) No established target; track against the oncology team’s response criteria Expected change (claimed): the outcome lemongrass is purported to affect No human data show any change with lemongrass; imaging and markers follow the oncology schedule

Qualitative markers:

  • Skin rash, itching or redness, especially after topical oil use
  • Urination frequency, thirst and signs of dehydration
  • Stomach upset or heartburn after tea or extract
  • Mouth comfort, gum bleeding and signs of oral thrush during treatment
  • Energy, appetite and general well-being during cancer treatment

Emerging Research

  • No registered cancer trials: A ClinicalTrials.gov search (October 2026) found no trial of lemongrass, its oil or citral in people with cancer; the 28 lemongrass-related registrations concern dental, anxiety, wound, smoking and exercise outcomes. Any first human cancer study would be the first direct evidence on this goal.
  • Citral nanoformulations: Citral in lipid nanocarriers (tiny fat-based particles) slowed breast tumors and their spread to the lungs in mice more than free citral (Nordin et al., 2020). Better delivery could strengthen the case; human bioavailability data are still absent.
  • Stem-like cancer cells: Citral’s inhibition of ALDH1A3 (Thomas et al., 2016) points to a biomarker-selected test in breast cancer, which could show whether any benefit is confined to ALDH1A3-high tumors.
  • Chemotherapy combinations: Mouse data show added effect with FOLFOX (Ruvinov et al., 2019), but metformin diminished citral’s effect in cells (Duan et al., 2021); combinations could strengthen or weaken the case. Human pharmacokinetic data, called for in a 2015 review by Ekpenyong et al., remain missing.
  • Myrcene at dietary exposure: Food-occurrence data for β-myrcene are judged insufficient for human risk assessment (Okaru & Lachenmeier, 2017); clearer exposure data could weaken the case for high-myrcene oils or ease the concern.
  • Kidney signal replication: The eGFR decline comes from one group’s uncontrolled study (Ekpenyong et al., 2015); a placebo-controlled replication would show whether daily tea truly lowers kidney function.

Conclusion

Lemongrass is a cooking herb and tea. Its reputation as a cancer remedy rests on laboratory dishes and rodents: extracts, the oil and its main scent compound kill cancer cells, slow human tumors grown in mice, reduce precancerous changes in animals given cancer-causing chemicals, and add to some chemotherapy drugs. None of this has been tested in people with cancer, and how much of it reaches a tumor is unknown, so any anticancer benefit is speculative. The best-supported human benefits, less gum inflammation with an oil mouthwash and less anxiety from its scent, concern comfort, not tumors.

The human safety record at food amounts is reassuring but not clean. A small uncontrolled volunteer study found kidney filtering fell with daily tea; the oil is a skin allergen; a minor oil component causes tumors in rodents at high doses; and animal studies show harm to the fetus and, at very high oil doses, to the liver and stomach. Effects on cancer drugs are unknown. The largest documented hazard is indirect: relying on alternative remedies instead of standard treatment for curable cancers shortens survival.

The evidence base is small, mostly animal and cell work from academic laboratories; no company or insurer has funded a human cancer trial, supplement sellers have amplified laboratory findings, and the main cautionary herb summary comes from a cancer center earning from conventional care. For a risk-aware person with cancer, lemongrass is a pleasant food with an unproven anticancer role and a few manageable safety signals.

Top - Benefits - Risks - Protocol